Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy
Free accessResearch articleFirst published online April, 2012
Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy
Interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and viral factors can predict sustained virological response (SVR) in HCV genotype-1 (HCV-1) patients receiving 48 weeks of pegylated interferon and ribavirin. Whether these factors would identify those patients who can benefit from a shorter duration of therapy remains unclear.
Methods
Treatment-naive HCV-1 patients (n=662) receiving 24 or 48 weeks of combination therapy were enrolled. Baseline demographic data, HCV viral load, IL28B SNP genotypes (rs8099917), duration of therapy and rapid virological response (RVR) were evaluated to predict SVR. The SVR rates were further stratified by the independent factors and compared.
Results
The IL28B rs8099917 TT genotype, low baseline viral load (HCV RNA≤600,000 IU/ml), RVR and 48-week therapy independently predicted SVR. In RVR patients with the IL28B rs8099917 TT genotype, the SVR rate of 24-week therapy was comparable to 48-week therapy (95% versus 99%; P=0.21) at low baseline viral load, but was inferior to 48-week therapy (70% versus 97%; P<0.001) at high baseline viral load. In non-RVR patients, the SVR rate of 24-week therapy was inferior to 48-week therapy for those with the IL28B rs8099917 TT genotype but high baseline viral load (23% versus 62%; P<0.001), and those with the IL28B rs8099917 GT/GG genotype but low baseline viral load (0% versus 33%; P=0.02).
Conclusions
HCV-1 patients simultaneously bearing the IL28B rs8099917 TT genotype, low baseline viral load and RVR can benefit from a shorter duration of combination therapy.
References
1.
LauerG.M., WalkerB.D.Hepatitis C virus infection. N Engl J Med2001; 345: 41–52.
2.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
3.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
4.
HadziyannisS.J., SetteH.Jr., MorganT.R.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med2004; 140: 346–355.
5.
McHutchisonJ.G., LawitzE.J., ShiffmanM.L.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med2009; 361: 580–593.
6.
LiuC.H., LiuC.J., LinC.L.Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis2008; 47: 1260–1269.
7.
YuM.L., DaiC.Y., HuangJ.F.Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology2008; 47: 1884–1893.
8.
LiuC.J., ChuangW.L., LeeC.M.Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology2009; 136: 496–504.e3.
9.
McHutchisonJ.G., EversonG.T., GordonS.C.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med2009; 360: 1827–1838.
10.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
11.
McHutchisonJ.G., MannsM.P., MuirA.J.Telaprevir for previously treated chronic HCV infection. N Engl J Med2010; 362: 1292–1303.
12.
KwoP.Y., LawitzE.J., McConeJ.Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet2010; 376: 705–716.
13.
PoordadF., McConeJ.Jr., BaconB.R.SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1195–1206.
14.
BaconB.R., GordonS.C., LawitzE.Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1207–1217.
15.
GhanyM.G., StraderD.B., ThomasD.L., SeeffL.B.Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009; 49: 1335–1374.
16.
MorenoC., DeltenreP., PawlotskyJ.M., HenrionJ., AdlerM., MathurinP.Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol2010; 52: 25–31.
17.
GeD., FellayJ., ThompsonA.J.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature2009; 461: 399–401.
18.
TanakaY., NishidaN., SugiyamaM.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet2009; 41: 1105–1109.
19.
SuppiahV., MoldovanM., AhlenstielG.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet2009; 41: 1100–1104.
20.
RauchA., KutalikZ., DescombesP.Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology2010; 138: 1338–1345.e1–7.
21.
KurosakiM., TanakaY., NishidaN.Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol2011; 54: 439–448.
22.
ThompsonA.J., MuirA.J., SulkowskiM.S.Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology2010; 139: 120–129.e18.
23.
HsuC.S., HsuS.J., ChenH.C.Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A2011; 108: 3719–3724.
24.
RotimiC.N., JordeL.B.Ancestry and disease in the age of genomic medicine. N Engl J Med2010; 363: 1551–1558.
25.
WangL., McLeodH.L., WeinshilboumR.M.Genomics and drug response. N Engl J Med2011; 364: 1144–1153.
26.
BalagopalA., ThomasD.L., ThioC.L.IL28B and the control of hepatitis C virus infection. Gastroenterology2010; 139: 1865–1876.
27.
McHutchisonJ.G.The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver Int2011; 31Suppl 1: 29–35.
28.
HsuC.S., LiuC.H., LiuC.J.Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther2009; 14: 45–54.
29.
LiangC.C., LiuC.H., LinY.L., LiuC.J., ChiangB.L., KaoJ.H.Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. J Med Virol2011; 83: 1212–1220.
30.
McHutchisonJ.G., MannsM., PatelK.Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology2002; 123: 1061–1069.
31.
BedossaP., PoynardT.An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology1996; 24: 289–293.
32.
BarrettJ.C., FryB., MallerJ., DalyM.J.Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics2005; 21: 263–265.
33.
HayesC.N., KobayashiM., AkutaN.HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut2011; 60: 261–267.
34.
FarnikH., LangeC.M., SarrazinC., KronenbergerB., ZeuzemS., HerrmannE.Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol2010; 8: 884–890.
35.
StättermayerA.F., StauberR., HoferH.Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol2011; 9: 344–350.e2.
36.
HuangC.F., HuangJ.F., YangJ.F.Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol2011; doi:10.1016/j.jhep.2011.03.029.
